For decades, the go-to treatments for cancer have been chemotherapy, radiation and surgery — but some experts are calling ...

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

Tina Willits, now 53, thought she had just two years to live. Today, she is cancer-free — and she wants the world to know about the treatment that saved her.

As the founder and CEO of Immunocine Cancer Center, based in Cancún, Mexico, he has transformed his vision into reality with ...

Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

Checkpoint Therapeutics’ stock has seen a remarkable +60.26% year-to-date increase, far surpassing the S&P 500’s YTD performance of +26.86%. This highlights how well Checkpoint is positioning itself ...

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General ... How would you summarize your study for a lay audience? Immunotherapy has revolutionized the ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...